Your browser doesn't support javascript.
loading
A likelihood ratio approach for utilizing case-control data in the clinical classification of rare sequence variants: application to BRCA1 and BRCA2.
Zanti, Maria; O'Mahony, Denise G; Parsons, Michael T; Li, Hongyan; Dennis, Joe; Aittomäkkiki, Kristiina; Andrulis, Irene L; Anton-Culver, Hoda; Aronson, Kristan J; Augustinsson, Annelie; Becher, Heiko; Bojesen, Stig E; Bolla, Manjeet K; Brenner, Hermann; Brown, Melissa A; Buys, Saundra S; Canzian, Federico; Caputo, Sandrine M; Castelao, Jose E; Chang-Claude, Jenny; Czene, Kamila; Daly, Mary B; De Nicolo, Arcangela; Devilee, Peter; Dörk, Thilo; Dunning, Alison M; Dwek, Miriam; Eccles, Diana M; Engel, Christoph; Evans, D Gareth; Fasching, Peter A; Gago-Dominguez, Manuela; García-Closas, Montserrat; García-Sáenz, José A; Gentry-Maharaj, Aleksandra; Geurts-Giele, Willemina R R; Giles, Graham G; Glendon, Gord; Goldberg, Mark S; Garcia, Encarna B Gómez; Güendert, Melanie; Guénel, Pascal; Hahnen, Eric; Haiman, Christopher A; Hall, Per; Hamann, Ute; Harkness, Elaine F; Hogervorst, Frans B L; Hollestelle, Antoinette; Hoppe, Reiner.
Afiliação
  • Zanti M; Biostatistics Unit, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
  • O'Mahony DG; Biostatistics Unit, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
  • Parsons MT; Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
  • Li H; Cancer Control and Population Science, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
  • Dennis J; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Aittomäkkiki K; Department of Clinical Genetics, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
  • Andrulis IL; Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Anton-Culver H; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • Aronson KJ; Department of Medicine, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, CA, USA.
  • Augustinsson A; Department of Public Health Sciences, and Cancer Research Institute, Queen's University, Kingston, ON, Canada.
  • Becher H; Oncology, Department of Clinical Sciences in Lund, Lund University, Lund, Sweden.
  • Bojesen SE; Institute for Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Bolla MK; Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.
  • Brenner H; Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.
  • Brown MA; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Buys SS; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Canzian F; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Caputo SM; Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Castelao JE; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Chang-Claude J; School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, Queensland, Australia.
  • Czene K; Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Daly MB; Service de Génétique, Institut Curie, Paris, France.
  • De Nicolo A; Paris Sciences Lettres Research University, Paris, France.
  • Devilee P; Oncology and Genetics Unit, Instituto de Investigación Sanitaria Galicia Sur (IISGS), Xerencia de Xestion Integrada de Vigo-SERGAS, Vigo, Spain.
  • Dörk T; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Dunning AM; Cancer Epidemiology Group, University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Eccles DM; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Engel C; Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA, USA.
  • Evans DG; Center for Omics Sciences, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Fasching PA; Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands.
  • Gago-Dominguez M; Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.
  • García-Closas M; Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
  • García-Sáenz JA; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
  • Gentry-Maharaj A; School of Life Sciences, University of Westminster, London, UK.
  • Geurts-Giele WRR; Faculty of Medicine, University of Southampton, Southampton, UK.
  • Giles GG; Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany.
  • Glendon G; LIFE - Leipzig Research Centre for Civilization Diseases, University of Leipzig, Leipzig, Germany.
  • Goldberg MS; Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
  • Garcia EBG; North West Genomics Laboratory Hub, Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
  • Güendert M; Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, University Hospital Erlangen, Erlangen, Germany.
  • Guénel P; Genomic Medicine Group, International Cancer Genetics and Epidemiology Group, Fundación Pública Galega de Medicina Xenómica, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain.
  • Hahnen E; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA.
  • Haiman CA; Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Centro Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Hall P; MRC Clinical Trials Unit, Institute of Clinical Trials & Methodology, University College London, London, UK.
  • Hamann U; Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Harkness EF; Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia.
  • Hogervorst FBL; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.
  • Hollestelle A; Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.
  • Hoppe R; Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada.
Hum Mutat ; 20232023.
Article em En | MEDLINE | ID: mdl-38725546
ABSTRACT
A large number of variants identified through clinical genetic testing in disease susceptibility genes, are of uncertain significance (VUS). Following the recommendations of the American College of Medical Genetics and Genomics (ACMG) and Association for Molecular Pathology (AMP), the frequency in case-control datasets (PS4 criterion), can inform their interpretation. We present a novel case-control likelihood ratio-based method that incorporates gene-specific age-related penetrance. We demonstrate the utility of this method in the analysis of simulated and real datasets. In the analyses of simulated data, the likelihood ratio method was more powerful compared to other methods. Likelihood ratios were calculated for a case-control dataset of BRCA1 and BRCA2 variants from the Breast Cancer Association Consortium (BCAC), and compared with logistic regression results. A larger number of variants reached evidence in favor of pathogenicity, and a substantial number of variants had evidence against pathogenicity - findings that would not have been reached using other case-control analysis methods. Our novel method provides greater power to classify rare variants compared to classical case-control methods. As an initiative from the ENIGMA Analytical Working Group, we provide user-friendly scripts and pre-formatted excel calculators for implementation of the method for rare variants in BRCA1, BRCA2 and other high-risk genes with known penetrance.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Proteína BRCA1 / Predisposição Genética para Doença / Proteína BRCA2 Limite: Female / Humans Idioma: En Revista: Hum Mutat Assunto da revista: GENETICA MEDICA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Chipre

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Proteína BRCA1 / Predisposição Genética para Doença / Proteína BRCA2 Limite: Female / Humans Idioma: En Revista: Hum Mutat Assunto da revista: GENETICA MEDICA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Chipre